{"product_id":"tb-500-thymosin-beta-4-5mg-pen-test","title":"TB-500 (Thymosin Beta 4) | 15 Mg Pen","description":"\u003cp\u003eTB-500 is a synthetic peptide modeled on thymosin beta-4 (Tβ4) biology and is explored in regenerative research for its relationship to cytoskeletal dynamics, cell migration, and tissue-remodeling endpoints. In controlled preclinical settings, it is commonly used in study designs that track angiogenesis-linked signaling, collagen organization, and recovery-phase marker patterns across musculoskeletal and connective tissue models. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eCell migration and tissue-remodeling endpoints linked to actin-regulated cytoskeletal dynamics.\u003c\/li\u003e\n\u003cli\u003eAngiogenesis-related signaling context monitored through VEGF\/perfusion readouts in models.\u003c\/li\u003e\n\u003cli\u003eConnective-tissue organization frameworks tracked via collagen alignment and ECM turnover markers.\u003c\/li\u003e\n\u003cli\u003eInflammation-balance research endpoints assessed through cytokine and stress-response readouts.\u003c\/li\u003e\n\u003cli\u003eRecovery and regeneration study designs evaluating structural repair kinetics in preclinical systems.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eTB-500\u003c\/strong\u003e is widely discussed as a research analog associated with \u003cstrong\u003ethymosin beta-4 (Tβ4)\u003c\/strong\u003e, a peptide involved in actin-binding biology and cellular motility. In regenerative and repair-oriented research, TB-500 is used as a tool compound to examine how cytoskeletal regulation intersects with wound repair, angiogenic signaling, and extracellular matrix (ECM) remodeling in controlled models.\u003c\/p\u003e\n\u003cp\u003eAcross preclinical studies, thymosin beta-4–related pathways are frequently investigated for their role in coordinating cell migration and tissue organization during recovery phases. Experimental readouts often include changes in angiogenesis markers, collagen\/ECM remodeling signals, and inflammation-related patterns that shape the repair microenvironment.\u003c\/p\u003e\n\u003cp\u003eTB-500 is presented here for controlled research and educational context only. It is not marketed as an approved therapeutic product, and reported observations can vary substantially by model, endpoints, and study design.\u003c\/p\u003e\n\u003ch2\u003eClinical Status\u003c\/h2\u003e\n\u003cp\u003eThymosin beta-4–related research includes extensive animal and in vitro investigation and limited human study contexts depending on indication and formulation. TB-500 is not presented here as an approved therapeutic product, and interpretation should remain study-specific and endpoint-driven.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003eHuman RCT \u003cspan\u003e▣\u003c\/span\u003e | Observational \u003cspan\u003e▣\u003c\/span\u003e | Animal ✔ | In vitro ✔ | Regulatory approval ☐\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eMechanistic narratives around thymosin beta-4 biology emphasize \u003cstrong\u003eactin binding and cytoskeletal regulation\u003c\/strong\u003e. In experimental systems, modulation of actin dynamics is used to frame hypotheses around cell motility, tissue organization, and repair-phase remodeling. In addition, angiogenesis-related signaling (often monitored via VEGF-linked readouts) is frequently evaluated in parallel within tissue injury and recovery paradigms.\u003c\/p\u003e\n\u003cp\u003eInflammation-balance context is also commonly monitored alongside structural repair markers, including cytokine panels and fibrosis-related signals. Reported effects depend on model choice, timing, route, and endpoint selection.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eAccelerated Tissue Repair And Regeneration:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003e\u003cb\u003e\u003cu\u003eTB 500 has been studied for its role in cellular migration and tissue regeneration\u003c\/u\u003e\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eacross multiple preclinical injury models. Research suggests it supports actin regulation, which is essential for cell movement and structural repair. In animal models, enhanced recovery of muscle fibers and connective tissue has been observed. Increased angiogenesis and improved collagen organization have also been documented. These mechanisms position TB 500 as a central peptide in regenerative biology research. Evidence type: Animal ▣ | In vitro ▣.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eActin Cytoskeleton Modulation:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eTB 500 is a synthetic analog of Thymosin Beta 4, a naturally occurring peptide involved in actin-binding dynamics. Laboratory studies indicate that it regulates G-actin polymerization, supporting cytoskeletal remodeling. This process is critical for wound closure, cell migration, and structural repair. In vitro research demonstrates improved cellular motility following exposure. The peptide’s actin-related activity is considered one of its primary mechanistic hooks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Angiogenesis And Blood Vessel Formation:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003ePreclinical studies show increased VEGF expression in tissue injury models. This upregulation contributes to new blood vessel formation and improved oxygen delivery to damaged areas. In animal research, enhanced capillary density has been observed following administration. Improved vascularization supports nutrient transport and tissue remodeling processes. Evidence derives primarily from animal and laboratory models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupport For Muscle Recovery Models:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eIn experimental muscle injury models, TB 500 has been observed to accelerate regeneration of damaged fibers. Studies report improved organization of muscle tissue architecture. Reduced scar tissue formation has been documented in certain animal trials. Enhanced satellite cell activation has also been explored. These findings contribute to its inclusion in performance and recovery research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eConnective Tissue And Tendon Research Applications:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eTB 500 has been studied in tendon and ligament injury models. Preclinical data indicate improved collagen fiber alignment and structural strength. Enhanced fibroblast migration has been documented in vitro. These cellular processes are essential for connective tissue remodeling. The peptide’s regenerative profile makes it relevant in musculoskeletal research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Inflammatory Signaling Modulation:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eIn animal models of tissue injury, reduced inflammatory markers such as TNF-α and IL-6 have been observed. Research suggests TB 500 may modulate NF-κB pathways involved in inflammatory signaling. This appears to support a balanced repair environment rather than excessive inflammation. Laboratory findings indicate regulation rather than suppression of immune activity. Evidence type: Animal ▣ | In vitro ▣.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReduced Fibrosis In Experimental Models:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eCertain preclinical studies suggest decreased fibrotic tissue formation following injury. Improved collagen matrix organization has been measured in histological assessments. Reduced scar tissue density has been observed in comparison groups. These findings indicate potential relevance in fibrosis-related research. Data remain primarily preclinical.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSystemic Distribution Profile:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eResearch suggests that TB 500 may exhibit systemic distribution beyond the site of administration. Animal pharmacokinetic models indicate broad tissue penetration. This characteristic differentiates it from localized growth factor approaches. The systemic effect profile supports its inclusion in whole-body recovery research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCardiac And Organ Tissue Research:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eTB 500 has been evaluated in experimental cardiac injury models. Preclinical data show improved cellular survival and reduced necrotic area following ischemic stress. Enhanced endothelial cell migration has been documented in laboratory settings. These findings are exploratory and remain within animal and in vitro contexts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eHigh Bioavailability Through Subcutaneous Administration:\u003c\/b\u003e\u003cspan\u003e \u003c\/span\u003eProvided in a stabilized pre-mixed injection pen for SubQ administration, supporting consistent experimental dosing. Subcutaneous delivery allows reliable systemic exposure in research models. The formulation avoids multi-step vial reconstitution and supports standardized protocols. Each unit is prepared fresh and intended strictly for research use only.\u003c\/li\u003e\n\u003cli\u003e\u003cbr\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Data\u003c\/h2\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%;\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eStudy\/model\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eCutaneous wound models (preclinical)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported faster wound-closure kinetics and remodeling-phase marker shifts in thymosin beta-4 study contexts (endpoint-dependent).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eAngiogenesis\/perfusion assays (preclinical \/ in vitro)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported increases in angiogenesis-associated signaling markers and endothelial migration behaviors in controlled systems.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eTendon\/ligament injury models (animal)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported improvements in collagen organization and structural remodeling readouts during recovery phases (study-dependent).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eSkeletal muscle injury paradigms (animal)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported shifts in muscle repair markers and reduced disorganization\/fibrosis signals in some model settings.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eInflammation marker panels (cell\/animal)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eReported changes in cytokine patterns and stress-response signaling context associated with repair microenvironment dynamics.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 37.8136%;\"\u003eCardiac ischemia \/ repair models (preclinical)\u003c\/td\u003e\n\u003ctd style=\"width: 62.1864%;\"\u003eThymosin beta-4 research contexts report tissue-preservation and repair signaling markers after ischemic stress (endpoint-dependent).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStack Suggestions\u003c\/h2\u003e\n\u003cp\u003eIn extended experimental designs, TB-500 is sometimes paired with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBPC-157 (repair-cascade and connective-tissue remodeling frameworks)\u003c\/li\u003e\n\u003cli\u003eGHK-Cu (ECM and dermal remodeling context)\u003c\/li\u003e\n\u003cli\u003eSS-31 or NAD+ (mitochondrial stress and redox-context marker panels in recovery designs)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eIn research contexts, tolerability notes for TB-500 are generally model- and route-dependent. Where administered, observations may include localized sensitivity or transient systemic effects. These notes are provided for general context only; they do not constitute medical guidance.\u003c\/p\u003e\n\u003cp\u003eInjection-site sensitivity: Temporary redness, swelling, or discomfort can occur in some settings.\u003cbr\u003eHeadache or fatigue: Transient effects have been noted anecdotally in certain protocols.\u003cbr\u003eDizziness or nausea: Occasional reports during early exposure windows in some settings.\u003cbr\u003eSensitivity reactions: Rare hypersensitivity-like responses are possible and warrant caution.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22074294\/\"\u003eThymosin β4: a multi-functional regenerative peptide\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17312817\/\"\u003eThymosin beta4 promotes endothelial cell migration and angiogenesis\u003c\/a\u003e — In vitro \/ mechanistic\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14554208\/\"\u003ePeptide-mediated effects in tendon healing contexts (thymosin-related repair biology)\u003c\/a\u003e — Animal \/ tissue repair context\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15136502\/\"\u003eThymosin beta4 and wound repair processes\u003c\/a\u003e — Review \/ mechanistic context\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16940182\/\"\u003eThymosin β4 and cardiac repair signaling in preclinical models\u003c\/a\u003e — Animal \/ cardiac repair context\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20350515\/\"\u003eThymosin β4 in tissue protection and remodeling: mechanistic perspectives\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19710984\/\"\u003eThymosin beta4 and inflammatory signaling modulation in repair contexts\u003c\/a\u003e — Preclinical \/ mechanistic\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20551510\/\"\u003eThymosin β4 and fibrosis\/remodeling marker patterns in injury models\u003c\/a\u003e — Animal \/ remodeling context\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=thymosin+beta+4+actin+cell+migration\"\u003eThymosin beta-4, actin, and cell migration literature search\u003c\/a\u003e — PubMed query\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=thymosin+beta+4+angiogenesis+VEGF\"\u003eThymosin beta-4 and angiogenesis\/VEGF literature search\u003c\/a\u003e — PubMed query\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003c\/li\u003e\n\u003cli\u003eIf you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.\u003c\/li\u003e\n\u003cli\u003eDiscontinue use if sensitivity occurs.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Peptoora","offers":[{"title":"Default Title","offer_id":61559766778186,"sku":"PE-GR-PEN-011","price":399.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/TB-500_5mg.png?v=1775794613","url":"https:\/\/peptoora.com\/fr\/products\/tb-500-thymosin-beta-4-5mg-pen-test","provider":"Peptoora LTD","version":"1.0","type":"link"}